FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	

	OMB Number:	3235-0287
	Estimated average burden	
ı	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

in reality and reality of the period of the			2. Issuer Name and Ticker or Trading Symbol RESMED INC [RMD]		ionship of Reporting Person(s) all applicable) Director	to Issuer	
(Last) RESMED INC.	.ast) (First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) $10/05/2020$	X	Officer (give title below) Chief Administrative	Other (specify below) Officer	
9001 SPECTRUM CENTER BLVD. (Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	dual or Joint/Group Filing (Che Form filed by One Reporting Form filed by More than One	Person	
(City)	CA (State)	92123 (Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities A Of (D) (Instr. 3,		A) or Disposed	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
ResMed Common Stock	10/05/2020		M ⁽¹⁾		5,919	A	\$57.76	142,047	D	
ResMed Common Stock	10/05/2020		S ⁽¹⁾		5,919	D	\$170.066(2)	136,128	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		or Dis	itive ities red (A) posed (Instr. 3,	6. Date Exerci Expiration Da (Month/Day/Yo	te	7. Title and An Securities Und Derivative Sec 3 and 4)	derlying	Derivative	Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
ResMed Common Stock Options	\$57.76	10/05/2020		М			5,919	11/11/2017 ⁽³⁾	11/16/2023	ResMed Common Stock	5,919	\$0	5,918	D	

Explanation of Responses:

- 1. The transaction was conducted under a Rule 10b5-1 plan.
- 2. This transaction was executed in multiple trades at prices ranging from \$168.72 to 171.06. The price reported above reflects the weighted average sale price.
- 3. Represents date options first became exercisable. Options vest 1/3 per year.

David Pendarvis, Chief Administrative Officer

10/06/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.